Back to Search
Start Over
Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases.
- Source :
-
Nature reviews. Urology [Nat Rev Urol] 2024 Jun; Vol. 21 (6), pp. 339-356. Date of Electronic Publication: 2024 Jan 31. - Publication Year :
- 2024
-
Abstract
- Identification of clinically positive pelvic lymph node metastases (cN+) in patients with muscle-invasive bladder cancer is currently challenging, as the diagnostic accuracy of available imaging modalities is limited. Conventional CT is still considered the gold-standard approach to diagnose lymph node metastases in these patients. The development of innovative diagnostic methods including radiomics, artificial intelligence-based models and molecular biomarkers might offer new perspectives for the diagnosis of cN+ disease. With regard to the treatment of these patients, multimodal strategies are likely to provide the best oncological outcomes, especially using induction chemotherapy followed by radical cystectomy and pelvic lymph node dissection in responders to chemotherapy. Additionally, the use of adjuvant nivolumab has been shown to decrease the risk of recurrence in patients who still harbour ypT2-T4a and/or ypN+ disease after surgery. Alternatively, the use of avelumab maintenance therapy can be offered to patients with unresectable cN+ tumours who have at least stable disease after induction chemotherapy alone. Lastly, patients with cN+ tumours who are not responding to induction chemotherapy are potential candidates for receiving second-line treatment with pembrolizumab.<br /> (© 2024. Springer Nature Limited.)
Details
- Language :
- English
- ISSN :
- 1759-4820
- Volume :
- 21
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Nature reviews. Urology
- Publication Type :
- Academic Journal
- Accession number :
- 38297079
- Full Text :
- https://doi.org/10.1038/s41585-023-00842-y